912 related articles for article (PubMed ID: 27823972)
1. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
2. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
3. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
[TBL] [Abstract][Full Text] [Related]
4. Editorial: γδ T Cells in Cancer.
Coffelt SB; Kabelitz D; Silva-Santos B; Kuball J; Born W; Bank I
Front Immunol; 2020; 11():602411. PubMed ID: 33329597
[No Abstract] [Full Text] [Related]
5. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
Li Y; Li G; Zhang J; Wu X; Chen X
Front Immunol; 2020; 11():619954. PubMed ID: 33664732
[TBL] [Abstract][Full Text] [Related]
6. Prospects for immunotherapy of acute myeloid leukemia using γδ T cells.
Halim L; Parente-Pereira AC; Maher J
Immunotherapy; 2017 Jan; 9(2):111-114. PubMed ID: 28128710
[No Abstract] [Full Text] [Related]
7. Cancer immunotherapy with γδ T cells: many paths ahead of us.
Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
[TBL] [Abstract][Full Text] [Related]
8. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
9. Systemic β-Adrenergic Receptor Activation Augments the
Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
Front Immunol; 2019; 10():3082. PubMed ID: 32038628
[TBL] [Abstract][Full Text] [Related]
10. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
Rei M; Pennington DJ; Silva-Santos B
Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
[TBL] [Abstract][Full Text] [Related]
11. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.
Paul S; Lal G
Int J Cancer; 2016 Sep; 139(5):976-85. PubMed ID: 27012367
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
13. γδ T cell-based anticancer immunotherapy: progress and possibilities.
Meraviglia S; Lo Presti E; Dieli F; Stassi G
Immunotherapy; 2015; 7(9):949-51. PubMed ID: 26569071
[No Abstract] [Full Text] [Related]
14. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
15. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis.
Wakita D; Sumida K; Iwakura Y; Nishikawa H; Ohkuri T; Chamoto K; Kitamura H; Nishimura T
Eur J Immunol; 2010 Jul; 40(7):1927-37. PubMed ID: 20397212
[TBL] [Abstract][Full Text] [Related]
17. γδ T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity.
Janssen A; Villacorta Hidalgo J; Beringer DX; van Dooremalen S; Fernando F; van Diest E; Terrizi AR; Bronsert P; Kock S; Schmitt-Gräff A; Werner M; Heise K; Follo M; Straetemans T; Sebestyen Z; Chudakov DM; Kasatskaya SA; Frenkel FE; Ravens S; Spierings E; Prinz I; Küppers R; Malkovsky M; Fisch P; Kuball J
Cancer Immunol Res; 2020 Apr; 8(4):530-543. PubMed ID: 32019779
[TBL] [Abstract][Full Text] [Related]
18. How tumors might withstand γδ T-cell attack.
Capietto AH; Martinet L; Fournié JJ
Cell Mol Life Sci; 2011 Jul; 68(14):2433-42. PubMed ID: 21547501
[TBL] [Abstract][Full Text] [Related]
19. Anti-lymphoma effect of gammadelta T cells.
Kunzmann V; Wilhelm M
Leuk Lymphoma; 2005 May; 46(5):671-80. PubMed ID: 16019504
[TBL] [Abstract][Full Text] [Related]
20. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
Martinet L; Poupot R; Fournié JJ
Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
